Massimo Cristofanilli

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients
    M Mego
    Department of Hematopathology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Cancer 101:1813-6. 2009
  2. pmc Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells
    Bisrat G Debeb
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mol Cancer 9:180. 2010
  3. ncbi Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes
    Massimo Cristofanilli
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 23:41-8. 2005
  4. doi Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 1439, USA
    Clin Cancer Res 16:1904-14. 2010
  5. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 33:S9-14. 2006
  6. ncbi Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Breast Cancer 4:415-9. 2004
  7. ncbi Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 9:471-8. 2004
  8. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
  9. ncbi Novel targeted therapies in inflammatory breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:2837-9. 2010
  10. ncbi Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:1122-8. 2005

Collaborators

Detail Information

Publications101 found, 100 shown here

  1. pmc Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients
    M Mego
    Department of Hematopathology, University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Br J Cancer 101:1813-6. 2009
    ..Circulating tumour cells (CTCs) are an independent predictor of survival in metastatic breast cancer (MBC) patients. The aim of this study was to test the hypothesis that CTCs are associated with the risk of VTE in MBC patients...
  2. pmc Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells
    Bisrat G Debeb
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mol Cancer 9:180. 2010
    ..Herein we fully characterize cancer stem cell-like features in 293T human embryonic kidney cells...
  3. ncbi Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes
    Massimo Cristofanilli
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 4009, USA
    J Clin Oncol 23:41-8. 2005
    ..To investigate the impact of histologic type invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) on response to primary chemotherapy (PC) and long-term outcome...
  4. doi Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 1439, USA
    Clin Cancer Res 16:1904-14. 2010
    ..This phase II randomized trial evaluated the efficacy and tolerability of anastrozole combined with gefitinib or anastrozole with placebo in women with hormone receptor-positive metastatic breast cancer (MBC)...
  5. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 33:S9-14. 2006
    ..Larger studies are needed to confirm these data and evaluate the use of CTC detection in monitoring treatment and furthering our understanding of breast cancer biology when combined with other diagnostic technologies...
  6. ncbi Paclitaxel improves the prognosis in estrogen receptor negative inflammatory breast cancer: the M. D. Anderson Cancer Center experience
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Clin Breast Cancer 4:415-9. 2004
    ..04). It may be concluded that the addition of paclitaxel to anthracycline-based therapy resulted in a statistically significant improvement in outcome in patients with ER-negative inflammatory breast cancer...
  7. ncbi Breast cancer highlights: key findings from the San Antonio Breast Cancer Symposium: a U.S. perspective
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Oncologist 9:471-8. 2004
    ....
  8. ncbi Circulating tumor cells, disease progression, and survival in metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 351:781-91. 2004
    ..We tested the hypothesis that the level of circulating tumor cells can predict survival in metastatic breast cancer...
  9. ncbi Novel targeted therapies in inflammatory breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:2837-9. 2010
    ..Further investigation is needed to confirm the efficacy of lapatinib...
  10. ncbi Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 103:1122-8. 2005
    ....
  11. ncbi Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:1420-30. 2005
    ....
  12. ncbi A nonreplicating adenoviral vector that contains the wild-type p53 transgene combined with chemotherapy for primary breast cancer: safety, efficacy, and biologic activity of a novel gene-therapy approach
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 107:935-44. 2006
    ....
  13. pmc Circulating tumor cells in breast cancer: Advanced tools for "tailored" therapy?
    Massimo Cristofanilli
    The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 103:17073-4. 2006
  14. ncbi Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1436-44. 2007
    ..The authors compared the prognostic features of IBC and non-IBC locally advanced breast cancer (LABC) to gain insight into the biology of this disease entity...
  15. ncbi Angiogenesis modulation in cancer research: novel clinical approaches
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Nat Rev Drug Discov 1:415-26. 2002
    ..Here, we discuss methods for monitoring the biological activity of angiogenic modulators, and innovative approaches to trial design that might facilitate the integration of these agents into anticancer therapy...
  16. doi The biological information obtainable from circulating tumor cells
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230, USA
    Breast 18:S38-40. 2009
    ..Those data suggest interesting observations in the biology of those cells and indicate the possibility to evaluate targeted therapies based on the genomic profiling of CTCs, particularly with regards to HER-2 determination...
  17. pmc Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations
    M Cristofanilli
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 19:1713-9. 2008
    ..We tested the activity of imatinib mesylate in MBC with overexpression of PDGFR or c-kit. Additionally, we sought to determine the biological correlates and immunomodulatory effects...
  18. ncbi Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:471-9. 2007
    ..We compared the prognostic significance of CTCs with clinical and laboratory measures of tumor burden and phenotypic subtype of disease...
  19. ncbi Update on the management of inflammatory breast cancer
    Massimo Cristofanilli
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 8:141-8. 2003
    ..Future therapeutic approaches should focus on these discoveries so that we can improve the overall prognosis for women with IBC...
  20. doi Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage
    Ricardo H Alvarez
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Cancer 116:1210-7. 2010
    ....
  21. ncbi Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors
    Valentina Guarneri
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 24:1037-44. 2006
    ..To evaluate whether hormonal receptor (HR) status can influence the prognostic significance of pathologic complete response (pCR)...
  22. ncbi Breast cancer molecular subtypes respond differently to preoperative chemotherapy
    Roman Rouzier
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Clin Cancer Res 11:5678-85. 2005
    ..The goal of this research was to determine if these different molecular subtypes of breast cancer also respond differently to preoperative chemotherapy...
  23. ncbi Epidermal growth factor receptor expression correlates with poor survival in patients who have breast carcinoma treated with doxorubicin-based neoadjuvant chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 104:676-81. 2005
    ..To the authors' knowledge there are few data that correlate the expression of the epidermal growth factor receptor (EGFR) with the outcome of patients who have breast carcinoma and are treated with anthracycline chemotherapy...
  24. ncbi The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer
    Thomas A Buchholz
    Department of Radiation Oncology, Breast Medical Oncology, Surgical Oncology, and Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:8398-402. 2005
    ....
  25. pmc Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer
    Dongwei Zhang
    Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:6639-48. 2009
    ..Epidermal growth factor receptor (EGFR) expression is an independent poor prognostic factor in IBC. The purpose of this study was to determine the effect on IBC tumorigenicity and metastasis of blocking the EGFR pathway...
  26. ncbi Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks
    Marjorie C Green
    The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 424, Houston, TX 77030, USA
    J Clin Oncol 23:5983-92. 2005
    ....
  27. doi Inflammatory breast cancer: the disease, the biology, the treatment
    Fredika M Robertson
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 60:351-75. 2010
    ..This review examines IBC's unique clinical presentation, pathology, epidemiology, imaging, and biology and details current multidisciplinary management of the disease, which comprises systemic therapy, surgery, and radiation therapy...
  28. doi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  29. doi 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer
    Ugo De Giorgi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Nucl Med 51:1213-8. 2010
    ..Our objective was to compare the predictive significance of (18)F-FDG PET/CT findings and circulating tumor cell (CTC) count in patients with bone metastases from breast cancer treated with standard systemic therapy...
  30. ncbi Central nervous system metastases in patients with high-risk breast carcinoma after multimodality treatment
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 101:1760-6. 2004
    ..D. Anderson Cancer Center (Houston, TX)...
  31. pmc Differential regulation of the aggressive phenotype of inflammatory breast cancer cells by prostanoid receptors EP3 and EP4
    Fredika M Robertson
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:2806-14. 2010
    ....
  32. ncbi Combined-modality treatment for isolated recurrences of breast carcinoma: update on 30 years of experience at the University of Texas M.D. Anderson Cancer Center and assessment of prognostic factors
    Emer O Hanrahan
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas
    Cancer 104:1158-71. 2005
    ..An analysis of prognostic factors for these patients also is presented...
  33. ncbi Kinetics of serum HER-2/neu changes in patients with HER-2-positive primary breast cancer after initiation of primary chemotherapy
    Chafika Mazouni
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77230 1439, USA
    Cancer 109:496-501. 2007
    ....
  34. doi Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers
    Giampaolo Bianchini
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 28:4316-23. 2010
    ....
  35. ncbi Evaluation of a CXCR4 antagonist in a xenograft mouse model of inflammatory breast cancer
    Balraj Singh
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Exp Metastasis 27:233-40. 2010
    ..05). However, CTCE-9908 as a single therapy inhibited organ-specific metastasis to leg (P < 0.05 by chi-squared test and by two-sample t-test)...
  36. ncbi Predictors of systemic recurrence and disease-specific survival after ipsilateral breast tumor recurrence
    Jeannie Shen
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 104:479-90. 2005
    ..Therefore, the management of isolated IBTR remains controversial. The objective of the current study was to identify determinants of systemic recurrence and DSS after IBTR...
  37. doi Pre-clinical studies of Notch signaling inhibitor RO4929097 in inflammatory breast cancer cells
    Bisrat G Debeb
    Department of Radiation Oncology, Unit 1202, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Breast Cancer Res Treat 134:495-510. 2012
    ....
  38. doi Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer
    Ugo De Giorgi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 12:264-9. 2012
    ....
  39. doi Prognostic value of initial clinical disease stage after achieving pathological complete response
    Shaheenah Dawood
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
    Oncologist 13:6-15. 2008
    ..Overall, patients who achieved a pCR had a low rate of recurrence. However, higher clinical stage and IBC were associated with worse outcomes in breast cancer patients who achieved a pCR after PST...
  40. ncbi Downregulation of the cyclin-dependent kinase inhibitor p27kip1 might correlate with poor disease-free and overall survival in inflammatory breast cancer
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230 1439, USA
    Clin Breast Cancer 7:326-30. 2006
    ..The objective of this study was to evaluate whether p27kip1 downregulation is a prognostic factor in patients with inflammatory breast carcinoma (IBC)...
  41. ncbi p53 expression as a prognostic marker in inflammatory breast cancer
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 10:6215-21. 2004
    ..We retrospectively analyze the expression of p53 as a prognostic marker to predict pathological complete response and survival in patients with IBC...
  42. pmc Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer
    Antonio Giordano
    Department of Hematopathology, Unit 0054, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
    Mol Cancer Ther 11:2526-34. 2012
    ..Moreover, an enrichment of CSCs was found in CD326(-)CD45(-) cells. Additional studies are needed to determine whether EMT-CTCs and CSCs have prognostic value in patients with HER2(+) MBCs treated with trastuzumab-based therapy...
  43. pmc Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer
    Naoki Hayashi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Clin Oncol 17:96-104. 2012
    ..The presence of ≥5 circulating tumor cells (CTCs) in 7.5 ml blood is a poor prognostic marker in metastatic breast cancer (MBC). However, the role of human epidermal growth factor receptor 2 (HER2) status in CTCs is not known...
  44. pmc Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
    ..We assessed the prognostic impact of CTCs according to different first-line systemic treatments, and explored their potential predictive value in MBC patients...
  45. doi Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer
    Ugo De Giorgi
    The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 27:3303-11. 2009
    ..In this study, we compared the prognostic value of CTC and FDG-PET/CT monitoring during systemic therapy for metastatic breast cancer (MBC)...
  46. doi Detection of minimal residual disease in blood and bone marrow in early stage breast cancer
    Savitri Krishnamurthy
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:3330-7. 2010
    ..In this study, the authors investigated the occurrence of CTCs and DTCs in women with early stage breast cancer and evaluated the correlation of their presence with other prognostic markers...
  47. ncbi Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy
    Bryan T Hennessy
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1000-6. 2006
    ..The purpose of the current study was to determine long-term outcome in patients achieving a pCR of cytologically proven inflammatory breast carcinoma ALN metastases after primary chemotherapy...
  48. doi Retrospective study of 18F-FDG PET/CT in the diagnosis of inflammatory breast cancer: preliminary data
    Selin Carkaci
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    J Nucl Med 50:231-8. 2009
    ..Our objective was to retrospectively evaluate 18F-FDG PET/CT in the initial staging of inflammatory breast cancer (IBC)...
  49. ncbi Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3315-9. 2005
    ..A secondary objective was to determine whether the quantitative RT-PCR data correlated with immunohistochemistry assay data regarding estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 status...
  50. doi Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 113:2422-30. 2008
    ..The aim of the current study was to assess the prognostic value of baseline circulating tumor cells (CTCs) in a large cohort of patients with newly diagnosed metastatic breast cancer (MBC)...
  51. doi Prognostic significance of HER-2 status in women with inflammatory breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer 112:1905-11. 2008
    ..The purpose of this study was to define the prognostic impact of HER-2 status on survival outcomes of patients with IBC...
  52. ncbi Effective local control and long-term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy
    Jeannie Shen
    Department of Surgical Oncology, Unit 444, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Ann Surg Oncol 11:854-60. 2004
    ..This study was conducted to assess the outcome of a carefully selected group of patients who presented with breast cancer involving the skin and who had breast conservation therapy (BCT) following neoadjuvant chemotherapy...
  53. ncbi Biologic markers in axillary node-negative breast cancer: differential expression in invasive ductal carcinoma versus invasive lobular carcinoma
    Ana Maria Gonzalez-Angulo
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 7:396-400. 2006
    ....
  54. pmc Serum HER2 levels determined by two methods in patients with metastatic breast cancer
    Naoki Hayashi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Clin Oncol 17:55-62. 2012
    ..We prospectively assessed the prognostic value of serum HER2 levels in MBC using two methods, enzyme immunoassay (EIA) and chemiluminescence immunoassay (CLIA)...
  55. doi Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome
    Yun Gong
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:5476-84. 2011
    ..In this retrospective study, the authors examined EZH2 expression in IBC tumors and evaluated the relation between EZH2 expression and patient survival...
  56. ncbi Suberoylanilide hydroxamic acid blocks self-renewal and homotypic aggregation of inflammatory breast cancer spheroids
    Fredika M Robertson
    The Morgan Welch Inflammatory Breast Cancer Research Program, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:2760-7. 2010
    ....
  57. ncbi Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer
    Aman U Buzdar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 424, Houston, TX 77030, USA
    J Clin Oncol 23:3676-85. 2005
    ....
  58. ncbi A Phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with metastatic breast carcinoma
    Francisco J Esteva
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, TX 77030, USA
    Cancer 98:900-7. 2003
    ..The objective of the current study was to determine the antitumor activity, safety, and pharmacokinetic (PK) profile of exatecan mesylate in patients with anthracycline-resistant and taxane-resistant, metastatic breast carcinoma...
  59. ncbi Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    J Clin Oncol 20:1800-8. 2002
    ..To evaluate the safety and efficacy of weekly docetaxel plus trastuzumab in women with HER-2-overexpressing metastatic breast cancer. Efficacy was correlated with serum HER-2 extracellular domain (ECD) levels...
  60. ncbi Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
    Takayuki Iwamoto
    Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res Treat 125:785-95. 2011
    ..IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC...
  61. ncbi Trends for inflammatory breast cancer: is survival improving?
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030 4009, USA
    Oncologist 12:904-12. 2007
    ..Clinical trials focusing on the management of this aggressive disease are warranted. Disclosure of potential conflicts of interest is found at the end of this article...
  62. ncbi Phase I study of eniluracil and oral 5-fluorouracil in combination with docetaxel in the treatment of patients with metastatic breast carcinoma
    Edgardo Rivera
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer 94:2321-6. 2002
    ....
  63. ncbi Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy
    Ana M Gonzalez-Angulo
    Department of Breast Medical Oncology, Unit 424, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    J Clin Oncol 23:7098-104. 2005
    ..To identify clinicopathological factors predictive of distant metastasis in patients who had a pathologic complete response (pCR) after neoadjuvant chemotherapy (NC)...
  64. doi Prognostic value of body mass index in locally advanced breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology, Division of Quantitative Sciences, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:1718-25. 2008
    ..The analysis includes the subsets of inflammatory (IBC) and noninflammatory (non-IBC LABC) breast cancer...
  65. ncbi CD44 expression is associated with increased survival in node-negative invasive breast carcinoma
    Leslie K Diaz
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 11:3309-14. 2005
    ..The purpose of this study was to evaluate the prognostic significance of CD44 isoforms in early-stage, lymph node-negative invasive breast carcinoma...
  66. ncbi A Phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a Phase II study as first-line therapy in metastatic breast cancer
    Jonathan C Trent
    Departments of Sarcoma Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:2426-34. 2003
    ..For Phase II, the purpose was to determine the safety and efficacy of this combination as first-line treatment in patients with metastatic breast cancer (MBC)...
  67. pmc A phase 1 study of weekly everolimus (RAD001) in combination with docetaxel in patients with metastatic breast cancer
    Stacy Moulder
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:2378-84. 2012
    ..Inhibition of mammalian target of rapamycin with everolimus may improve the efficacy of taxanes. Everolimus and docetaxel are both metabolized by CYP3A4, which could result in a pharmacokinetic (PK) interaction...
  68. pmc Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy
    Michal Mego
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 130:808-16. 2012
    ..In summary, our results demonstrate that CTCs with EMT phenotype may occur in the peripheral circulation of patients with PBC and that NAT is unable to eliminate CTCs undergoing EMT...
  69. ncbi Nipple aspirate fluid cytology in breast carcinoma
    Savitri Krishnamurthy
    Department of Pathology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 99:97-104. 2003
    ..Cytologic-histologic correlations of NAF were performed in only a few studies...
  70. ncbi Feasibility and utility of using chromosomal aneusomy to further define the cytologic categories in nipple aspirate fluid specimens: a preliminary study
    Savitri Krishnamurthy
    Department of Cytopathology, Unit 53, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Cancer 102:322-7. 2004
    ....
  71. doi HER2 status predicts the presence of circulating tumor cells in patients with operable breast cancer
    Julie E Lang
    Department of Surgical Oncology, MD Anderson Cancer Center, Advanced Research Center for Microscopic Disease, The University of Texas, Houston, TX 77030, USA
    Breast Cancer Res Treat 113:501-7. 2009
    ..We hypothesized that primary tumor characteristics would predict the likelihood of identifying CTCs in patients with operable breast cancer...
  72. pmc Primary breast cancer patients with high risk clinicopathologic features have high percentages of bone marrow epithelial cells with ALDH activity and CD44⁺CD24lo cancer stem cell phenotype
    James M Reuben
    Department of Hematopathology, Unit 54, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Eur J Cancer 47:1527-36. 2011
    ..Therefore, we assessed the presence of Aldefluor(+) epithelial (CD326(+)CD45(dim)) cells for the presence of the CD44(+)CD24(lo) phenotype in BM of patients with primary breast cancer (PBC)...
  73. pmc Mesenchymal stem cells promote mammosphere formation and decrease E-cadherin in normal and malignant breast cells
    Ann H Klopp
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 5:e12180. 2010
    ..These cells can be enriched by growth as "mammospheres" in three-dimensional cultures...
  74. doi Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells
    Michal Mego
    Departments of Hematopathology, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 129:417-23. 2011
    ..We showed that some important metastatic disease characteristics are predictive of undetectable CTC status in MBC...
  75. ncbi High and differential expression of HER-2/neu extracellular domain in bilateral ductal fluids from women with unilateral invasive breast cancer
    Henry M Kuerer
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:601-5. 2003
    ..Breast ductal fluid can be obtained from women by simple nipple aspiration and may be useful for analyzing the microenvironment of the breast...
  76. pmc Locoregional treatment outcomes after multimodality management of inflammatory breast cancer
    Ian J Bristol
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 72:474-84. 2008
    ....
  77. ncbi Systemic treatments for inflammatory breast cancer
    Charles H Yang
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Breast Dis 22:55-65. 2005
    ..In this review, we discuss some recent developments in the use of systemic therapies for inflammatory breast cancer...
  78. ncbi Phase I/II study of G3139 (Bcl-2 antisense oligonucleotide) in combination with doxorubicin and docetaxel in breast cancer
    Stacy L Moulder
    Department of Breast Medical Oncology, Pathology, Surgical Oncology, Radiation Oncology and Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 14:7909-16. 2008
    ..We evaluated the efficacy and safety of a Bcl-2 antisense oligonucleotide, G3139, in combination with doxorubicin (A) and docetaxel (T) in patients with locally advanced breast cancer (LABC)...
  79. ncbi Integrating circulating tumor cell assays into the management of breast cancer
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Curr Treat Options Oncol 8:89-95. 2007
    ..Large prospective trials are needed to further understand its biology and confirm its role as a predictive and prognostic marker before we can incorporate it into the conventional staging system...
  80. ncbi Chest wall recurrence after mastectomy does not always portend a dismal outcome
    Anees Chagpar
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Surg Oncol 10:628-34. 2003
    ..Chest wall recurrence (CWR) after mastectomy often forecasts a grim prognosis. Predictors of outcome after CWR, however, are not clear...
  81. ncbi Minimal clinical benefit of single agent Orathecin (Rubitecan) in heavily pretreated metastatic breast cancer
    Silwan Chedid
    Department of Breast Medical Oncology, M D Anderson Cancer Center, The University of Texas, 1515 Holcombe Boulevard, Unit 424, Houston, TX, 77030 4095, USA
    Cancer Chemother Pharmacol 57:540-4. 2006
    ..The purpose of this phase II study was to evaluate the efficacy and tolerability of Orathecin, an oral camptothecin analog that has exhibited antitumor activity in breast cancer patients during preclinical studies...
  82. ncbi Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy
    Thomas A Buchholz
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer J 9:33-41. 2003
    ..We investigated whether changes in tumor cell apoptosis and Bcl-2 expression immediately after chemotherapy correlated with response to breast cancer treatment...
  83. doi Defining the clinical diagnosis of inflammatory breast cancer
    S Eva Singletary
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Semin Oncol 35:7-10. 2008
    ..Accurate diagnosis is critically important, as multimodal therapy can significantly improve outcomes if instituted early enough...
  84. ncbi Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients
    Antonio Giordano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
    Breast Cancer Res Treat 129:451-8. 2011
    ..This study may support the concept that the number of CTCs, along with the biologic characteristics, needs to be carefully taken into account in future analysis...
  85. doi Primary peritoneal serous carcinoma presenting as inflammatory breast cancer
    Ibrahim Khalifeh
    Department of Pathology, MD Anderson Cancer Center, Houston, Texas, USA
    Breast J 15:176-81. 2009
    ..To our knowledge, this is the first reported case of an extramammary primary malignancy that not only presented as inflammatory breast cancer but also was diagnosed and initially treated as such...
  86. ncbi What progress have we made in managing inflammatory breast cancer?
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology (Williston Park) 21:673-9; discussion 679-80, 686-7. 2007
    ..This review examines the limitations of the current definition of IBC, explores our current understanding of the biology of IBC, and reviews the many exciting advances in locoregional and systemic treatment of IBC...
  87. doi Cyclooxygenase-2 expression in primary breast cancers predicts dissemination of cancer cells to the bone marrow
    Anthony Lucci
    Department of Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res Treat 117:61-8. 2009
    ....
  88. doi Circulating tumor cells as prognostic marker in metastatic breast cancer
    Eleni Andreopoulou
    University of Texas MD Anderson Cancer Center, Department of Breast Medical Oncology, 1155 Herman P Pressler, CPB5 3494 Houston, TX 77230, USA
    Expert Rev Anticancer Ther 10:171-7. 2010
    ..Considerable progress has been already accomplished which should lead to further noninvasive, real-time monitoring of these rare events in the adjuvant and metastatic settings...
  89. ncbi Factors predicting additional disease in the axilla in patients with positive sentinel lymph nodes after neoadjuvant chemotherapy
    Jacqueline S Jeruss
    Department Surgical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:2646-54. 2008
    ....
  90. ncbi Jun activation domain binding protein 1 expression is associated with low p27(Kip1)levels in node-negative breast cancer
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 9:5652-9. 2003
    ....
  91. ncbi Lack of activity of stealth liposomal doxorubicin in the treatment of patients with anthracycline-resistant breast cancer
    Edgardo Rivera
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Cancer Chemother Pharmacol 49:299-302. 2002
    ..We conducted a single-institution phase II clinical trial to determine the objective response rate, duration of response, time to progression, and overall survival in patients with anthracycline-resistant breast cancer treated with Doxil...
  92. ncbi Molecular prognostic factors for breast cancer metastasis and survival
    Francisco J Esteva
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Radiat Oncol 12:319-28. 2002
    ..We review the available data supporting the utility of established prognostic and predictive molecular factors, and discuss challenges for integrating novel molecular markers into clinical practice...
  93. doi Breast cancer in the asian Indian population of the United States: a call for screening and education
    Roshni Rao
    Breast J 14:402-3. 2008
  94. doi Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT
    Ukihide Tateishi
    Department of Nuclear Medicine, University of Texas M D Anderson Cancer Center, Unit 1263, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiology 247:189-96. 2008
    ..To retrospectively compare morphologic and metabolic changes in bone metastases in response to systemic therapy in patients with metastatic breast cancer (MBC) with integrated positron emission tomography (PET)/computed tomography (CT)...
  95. doi The medical treatment of inflammatory breast cancer
    Shaheenah Dawood
    Department of Medical Oncology, Dubai Hospital, Dubai, United Arab Emirates
    Semin Oncol 35:64-71. 2008
    ..Improved understanding of the biological features of the disease has allowed for the development of targeted therapies (eg, trastuzumab and lapatinib) that are changing the outcome of this aggressive disease...
  96. ncbi New generation of molecular prognostic and predictive tests for breast cancer
    Lajos Pusztai
    Department of Breast Medical Oncology, The University of Texas, M D Anderson Cancer Center, Houston, TX 77230 1439, USA
    Semin Oncol 34:S10-6. 2007
    ....
  97. ncbi Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival
    Daniel F Hayes
    Department of Internal Medicine and the Comprehensive Cancer Center, University of Michigan Health and Hospital System, Ann Arbor, Michigan 48109, USA
    Clin Cancer Res 12:4218-24. 2006
    ..In this study, additional follow-up data and CTC levels at subsequent follow-up visits were evaluated...
  98. ncbi Automated electrorotation to reveal dielectric variations related to HER-2/neu overexpression in MCF-7 sublines
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 8:615-9. 2002
    ..Experimental Design: P185(neu) was measured by Western blotting in MCF/neo cells and HER-2/neu transfectants MCF/HER2-11 and MCF/HER2-18. ROT spectra and cell membrane-specific capacitance were obtained for each cell line...
  99. ncbi Expression of c-kit proto-oncogene product in breast tissue
    Marwan A Yared
    Department of Pathology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Breast J 10:323-7. 2004
    ..These data suggest that c-kit may play a role in breast tumor progression and may therefore have diagnostic, prognostic, and therapeutic implications...
  100. ncbi Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors
    Lajos Pusztai
    Departments of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 009, USA
    Clin Cancer Res 9:2406-15. 2003
    ..33)P]dCTP-labeled cDNA probes were generated and hybridized to cDNA membrane microarrays that contained 30,000 human sequence clones, including 10,890 expressed sequence tags...
  101. ncbi The "microscopic" revolution in breast carcinoma
    Massimo Cristofanilli
    Cancer 103:877-80. 2005